SEARCH

SEARCH BY CITATION

References

  • Bernstein H. G., Baumann B., Danos P., Diekmann S., Bogerts B., Gundelfinger E. D. and Braunewell K. H. (1999) Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J. Neurocytol. 28, 655662.
  • Bertram L., Lill C. M. and Tanzi R. E. (2010) The genetics of Alzheimer disease: back to the future. Neuron 68, 270281.
  • Bibl M., Mollenhauer B., Esselmann H. et al. (2006) CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 11771187.
  • Bibl M., Esselmann H., Lewczuk P., Trenkwalder C., Otto M., Kornhuber J., Wiltfang J. and Mollenhauer B. (2010) Combined Analysis of CSF Tau, Abeta42, Abeta1-42% and Abeta1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int. J. Alzheimers. Dis. 2010 doi:10.4061/2010/761571.
  • Blandini F., Braunewell K. H., Manahan-Vaughan D., Orzi F. and Sarti P. (2004) Neurodegeneration and energy metabolism: from chemistry to clinics. Cell Death Differ. 11, 479484.
  • Braunewell K. H. (2012) The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease-old wine in new bottles. Front. Mol. Neurosci. 5, 20.
  • Braunewell K., Riederer P., Spilker C., Gundelfinger E. D., Bogerts B. and Bernstein H. G. (2001) Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement. Geriatr. Cogn. Disord. 12, 110116.
  • Bravo G. and Hebert R. (1997) Age- and education-specific reference values for the Mini-Mental and modified Mini-Mental State Examinations derived from a non-demented elderly population. Int. J. Geriatr. Psychiatry 12, 10081018.
  • Buerger K., Ewers M., Andreasen N. et al. (2005) Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 65, 15021503.
  • Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R. and Sudhof T. C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 16631667.
  • Clinton L. K., Blurton-Jones M., Myczek K., Trojanowski J. Q. and LaFerla F. M. (2010) Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 30, 72817289.
  • Crum R. M., Anthony J. C., Bassett S. S. and Folstein M. F. (1993) Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269, 23862391.
  • Dickson D. W. (2002) Dementia with Lewy bodies: neuropathology. J. Geriatr. Psychiatry Neurol. 15, 210216.
  • Dubois B., Feldman H. H., Jacova C. et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734746.
  • Engelborghs S. and Le Bastard N. (2012) The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol. Diagn. Ther. 16, 135141.
  • Giasson B. I., Forman M. S., Higuchi M., Golbe L. I., Graves C. L., Kotzbauer P. T., Trojanowski J. Q. and Lee V. M. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636640.
  • Gitler A. D., Bevis B. J., Shorter J. et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA 105, 145150.
  • Hansen L. A. and Samuel W. (1997) Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 48, 126132.
  • Hettiarachchi N. T., Parker A., Dallas M. L., Pennington K., Hung C. C., Pearson H. A., Boyle J. P., Robinson P. and Peers C. (2009) alpha-Synuclein modulation of Ca2 +  signaling in human neuroblastoma (SH-SY5Y) cells. J. Neurochem. 111, 11921201.
  • Hort J., Bartos A., Pirttila T. and Scheltens P. (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur. J. Neurol. 17, 9096.
  • Jack C. R., Jr, Albert M. S., Knopman D. S., McKhann G. M., Sperling R. A., Carrillo M. C., Thies B. and Phelps C. H. (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257262.
  • Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., Nishizawa M. and Ikeuchi T. (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 81, 608610.
  • Laterza O. F., Modur V. R., Crimmins D. L., Olander J. V., Landt Y., Lee J. M. and Ladenson J. H. (2006) Identification of novel brain biomarkers. Clin. Chem. 52, 17131721.
  • Lee V. M., Goedert M. and Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 11211159.
  • Lee V. M., Giasson B. I. and Trojanowski J. Q. (2004) More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 27, 129134.
  • Lee J. M., Blennow K., Andreasen N., Laterza O., Modur V., Olander J., Gao F., Ohlendorf M. and Ladenson J. H. (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin. Chem. 54, 16171623.
  • Mandal P. K., Pettegrew J. W., Masliah E., Hamilton R. L. and Mandal R. (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem. Res. 31, 11531162.
  • Maroteaux L., Campanelli J. T. and Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 28042815.
  • Martinez J., Moeller I., Erdjument-Bromage H., Tempst P. and Lauring B. (2003) Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 1737917387.
  • Mattson M. P. (2007) Calcium and neurodegeneration. Aging Cell 6, 337350.
  • McKeith I. G., Dickson D. W., Lowe J. et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 18631872.
  • McKhann G., Drachman D., Folstein M., Katzman R., Price D. and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939944.
  • Mollenhauer B., Cepek L., Bibl M. et al. (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 19, 164170.
  • Mollenhauer B., El-Agnaf O. M., Marcus K., Trenkwalder C. and Schlossmacher M. G. (2010) Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 4, 683699.
  • Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C. and Schlossmacher M. G. (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230240.
  • Nejatbakhsh N. and Feng Z.-P. (2011) Calcium binding protein-mediated regulation of voltage-gated calcium channels linked to human diseases. Acta Pharmacol. Sin. 32, 741748.
  • Nelson P. T., Jicha G. A., Kryscio R. J., Abner E. L., Schmitt F. A., Cooper G., Xu L. O., Smith C. D. and Markesbery W. R. (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J. Neurol. 257, 359366.
  • Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K. and Zetterberg H. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332335.
  • Querfurth H. W. and LaFerla F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329344.
  • Scherzer C. R., Grass J. A., Liao Z. et al. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc. Natl Acad. Sci. USA 105, 1090710912.
  • Schnurra I., Bernstein H. G., Riederer P. and Braunewell K. H. (2001) The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Neurobiol. Dis. 8, 900909.
  • Schulz-Schaeffer W. J. (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120, 131143.
  • Shaw L. M., Vanderstichele H., Knapik-Czajka M. et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403413.
  • Snider B. J., Fagan A. M., Roe C., Shah A. R., Grant E. A., Xiong C., Morris J. C. and Holtzman D. M. (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch. Neurol. 66, 638.
  • Spilker C. and Braunewell K. H. (2003) Calcium-myristoyl switch, subcellular localization, and calcium-dependent translocation of the neuronal calcium sensor protein VILIP-3, and comparison with VILIP-1 in hippocampal neurons. Mol. Cell. Neurosci. 24, 766778.
  • Stejskal D., Sporova L., Svestak M. and Karpisek M. (2011) Determination of serum visinin like protein-1 and its potential for the diagnosis of brain injury due to the stroke: a pilot study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub 155, 263268.
  • Stomrud E., Hansson O., Zetterberg H., Blennow K., Minthon L. and Londos E. (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch. Neurol. 67, 217223.
  • Sunderland T., Linker G., Mirza N. et al. (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 20942103.
  • Tapiola T., Alafuzoff I., Herukka S. K., Parkkinen L., Hartikainen P., Soininen H. and Pirttila T. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382389.
  • Tarawneh R., D'Angelo G., Macy E. et al. (2011) Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann. Neurol. 70, 274285.
  • Tarawneh R., Lee J. M., Ladenson J. H., Morris J. C. and Holtzman D. M. (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78, 709719.
  • Trojanowski J. Q. and Lee V. M. (2002) Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology 23, 457460.
  • Tymianski M. and Tator C. H. (1996) Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery 38, 11761195.
  • Wallin A. K., Blennow K., Andreasen N. and Minthon L. (2006) CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 21, 131138.
  • Wenham P. R., Price W. H. and Blandell G. (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 11581159.
  • The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. (1998) Consensus report of the working group on: “Molecular and biochemical markers of alzheimer's disease”. Neurobiol. Aging, 19, 109116.
  • Zhang Z. X., Zahner G. E., Roman G. C. et al. (2005) Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch. Neurol. 62, 447453.